Adlai Nortye Group Ltd. American Depositary Shares
ANL
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Last trade$9.47
Day change-$0.56 (-5.58%)
Day range$9.40 – $10.14
Volume175,165
Market cap$646M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for ANL.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for ANL.
Recent news
Company coverage with links to the original publishers.
Adlai Nortye announced clinical trial collaboration and supply agreements with Eli Lilly and Merck KGaA, Darmstadt, Germany to evaluate AN4035, a first-in-class pan-RAS(ON) inhibitor-based ADC, in combination with cetuximab in an ongoing global Phase I trial for CEACAM5-enriched RAS-addicted solid tumors. Both companies will supply cetuximab at no cost for their respective trial sites.
Adlai Nortye Ltd. (Nasdaq: ANL), a clinical-stage biotechnology company, announced a $150 million private placement of 11.32 million ADSs at $13.25 per share. The oversubscribed offering attracted participation from new institutional investors including Soleus Capital, Perceptive Advisors, and ADAR1 Capital Management, as well as existing investors. The company plans to use proceeds to advance its RAS-targeting therapies and next-generation cancer immunotherapies pipeline.
Adlai Nortye Ltd. announced that the first patient has been dosed in the United States in its Phase 1 clinical trial of AN9025, an oral pan-RAS(ON) inhibitor for advanced solid tumors with RAS mutations. The trial is being conducted as a multi-regional clinical trial in collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd., with Adlai Nortye retaining ex-China rights and ASK Pharm holding rights in mainland China, Hong Kong, and Macao.
Adlai Nortye, a clinical-stage biotechnology company, will participate in two healthcare investor conferences in late 2025 and early 2026, presenting its innovative cancer therapy pipeline.
Adlai Nortye will present research on AN4035, a novel CEACAM5-targeting antibody drug conjugate, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston on October 25, 2025.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Aug 13, 2008
$0.25
Aug 29, 2008
unknown
May 14, 2008
$0.25
May 30, 2008
unknown
Feb 13, 2008
$0.25
Feb 29, 2008
unknown
Nov 14, 2007
$0.25
Nov 30, 2007
unknown
Aug 15, 2007
$0.25
Aug 31, 2007
unknown
Stock splits
Historical share-structure events and their execution dates.